Syneos Health Inc stock (US87162W1009): buyout closes and Nasdaq delisting ends its public market journey

Syneos Health Inc is set to disappear from Nasdaq after shareholders backed a $7.1 billion all?cash takeover by a private equity consortium. What the buyout and delisting mean for former and remaining investors in the US-listed clinical research specialist.

Syneos Health Inc is in the final phase of its life as a listed stock after investors approved an all?cash buyout valued at about $7.1 billion, with the acquisition by a consortium led by Elliott Investment Management, Patient Square Capital and Veritas Capital closing in late 2023, according to Reuters citing company filings as of 09/28/2023 and a related company release as of 09/28/2023 (Reuters as of 09/28/2023, Syneos Health investor relations as of 09/28/2023).

As part of the go?private transaction, Syneos Health Inc is expected to be delisted from Nasdaq, removing direct access for public shareholders to the stock and shifting ownership to the private equity buyers, according to the company’s closing announcement as of 09/28/2023 (Syneos Health investor relations as of 09/28/2023).

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Syneos Health Inc
• Sector/industry: Contract research organization (CRO) and biopharma services
• Headquarters/country: Morrisville, North Carolina, United States
• Core markets: Clinical development and commercialization services for global biopharmaceutical companies
• Key revenue drivers: Outsourced clinical trial management, late-stage development projects, and commercial outsourcing contracts
• Home exchange/listing venue: Nasdaq (ticker: SYNH), pending delisting after go?private transaction
• Trading currency: US dollar (USD)

Syneos Health Inc: core business model

Syneos Health Inc positions itself as a full?service partner for pharmaceutical and biotechnology companies, combining a traditional contract research organization with commercialization services to support drugs from early clinical development through launch and post?approval, as outlined in company materials published on 03/01/2023 (Syneos Health company website as of 03/01/2023).

The group was formed in 2017 through the merger of INC Research and inVentiv Health, creating an integrated platform with clinical development capabilities spanning phase I to phase IV studies alongside medical affairs and commercial outsourcing support, according to its merger documentation released on 05/10/2017 (Syneos Health investor relations as of 05/10/2017).

Before the go?private deal, Syneos Health Inc reported operations through key business segments focused on clinical solutions and commercial solutions, serving large pharma, mid?sized biopharma and emerging biotech customers worldwide, as described in its Form 10?K for the year ended 12/31/2022 filed on 02/16/2023 (SEC Form 10?K as of 02/16/2023).

Operating from Morrisville, North Carolina, with a significant US footprint and global delivery centers, the company historically derived a substantial portion of its revenue from US?based customers and trials, underscoring its relevance to the US healthcare and capital markets, according to segment disclosures in its 2022 annual report published on 02/16/2023 (SEC Form 10?K as of 02/16/2023).

Main revenue and product drivers for Syneos Health Inc

Historically, the clinical solutions segment generated the bulk of Syneos Health Inc’s revenue by providing services such as study design, site and investigator selection, patient recruitment, data management, monitoring and biostatistics across therapeutic areas including oncology, central nervous system disorders and rare diseases, as outlined in the company’s 2022 Form 10?K published on 02/16/2023 (SEC Form 10?K as of 02/16/2023).

The commercial solutions unit contributed additional revenue by offering outsourcing for sales forces, market access consulting, medical affairs, and launch execution, targeting pharmaceutical and biotech clients that sought flexible go?to?market models, as described in Syneos Health Inc’s 2022 annual report released on 02/16/2023 (SEC Form 10?K as of 02/16/2023).

An important operational metric for Syneos Health Inc was its backlog of contracted business, which represented future revenue potential from signed customer contracts, and the company reported a total backlog of several billion dollars as of 12/31/2022, according to the Form 10?K filed on 02/16/2023 (SEC Form 10?K as of 02/16/2023).

Syneos Health Inc’s revenue was also influenced by macro trends such as the increasing complexity of clinical trials, continued outsourcing by large biopharma companies, and robust funding for emerging biotech firms, themes that the company highlighted in its 2022 annual report and investor presentation dated 03/01/2023 (Syneos Health investor presentation as of 03/01/2023).

Impact of the buyout and delisting on Syneos Health Inc’s equity story

The go?private transaction followed a strategic review that Syneos Health Inc launched after a period of weaker bookings and margin pressure, and the board ultimately agreed to the approximately $7.1 billion all?cash offer from the private equity consortium, according to a deal announcement dated 05/10/2023 (Syneos Health investor relations as of 05/10/2023).

Reuters reported on 05/10/2023 that the offer represented a premium to the stock’s prior trading levels but came after Syneos Health Inc had already experienced a significant share price decline over the preceding year, reflecting investor concerns about slowing net new business and execution challenges (Reuters as of 05/10/2023).

Shareholders approved the acquisition at a special meeting in September 2023, clearing the way for closing later that month and paving the path toward the stock’s removal from Nasdaq, according to the company’s shareholder vote results published on 09/13/2023 and the final closing release dated 09/28/2023 (Syneos Health investor relations as of 09/13/2023, Syneos Health investor relations as of 09/28/2023).

Once delisted, Syneos Health Inc no longer provides daily share price quotations or quarterly earnings updates to public markets, with financial and operational information becoming available mainly to the private equity owners and debt investors rather than public equity holders.

Why Syneos Health Inc still matters for US healthcare and capital markets

Although public trading in Syneos Health Inc shares is ending, the company continues to play a notable role in the US life sciences ecosystem by managing clinical trials and commercialization programs for many drug developers, which influence timelines for bringing new therapies to patients, according to descriptions in its 2022 Form 10?K filed on 02/16/2023 (SEC Form 10?K as of 02/16/2023).

For US investors, Syneos Health Inc also serves as an example of how private equity firms are increasingly active in acquiring mid?cap healthcare services companies, reshaping the investable universe on Nasdaq and the New York Stock Exchange, as illustrated by the 2023 take?private announced on 05/10/2023 (Syneos Health investor relations as of 05/10/2023).

The transaction may also influence peers in the contract research and commercialization space—such as other US?listed CROs—that compete for similar biopharma outsourcing budgets, though each company’s financial profile and strategic position remain distinct and need to be evaluated on their own merits.

Conclusion

Syneos Health Inc’s transition from a Nasdaq?traded stock to a privately held company via a roughly $7.1 billion all?cash buyout marks the end of an era for public investors while preserving the business as a significant player in global clinical research and commercialization services, according to deal documents dated 05/10/2023 and closing communications on 09/28/2023 (Syneos Health investor relations as of 05/10/2023, Syneos Health investor relations as of 09/28/2023). For US market participants, the case illustrates how private equity ownership can reshape the listed healthcare universe, while former shareholders now have to look elsewhere in the CRO and biopharma services space for comparable exposures.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.